Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
This study encompasses multicenter open-label, phase II trials.

Patients will be dispatched into 2 cohorts:

* Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2).

  43 patients are to be included in each arm.
* Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab.

  29 patients are to be included in this cohort.
Metastatic Cancer Lung|Advanced Lung Cancer|CBNPC Cancer
DRUG: Atezolizumab 1200 mg IV|DRUG: Tiragolumab 600 mg IV
Best overall response (BOR) rate, Best overall response (BOR) rate defined as the proportion of subjects with a partial response (PR) or complete response (CR) within 6 months of treatment initiation, based on RECIST v1.1 criteria, using blinded central review., after 6 months of treatment initiation
This study encompasses multicenter open-label, phase II trials.

Patients will be dispatched into 2 cohorts:

* Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2).

  43 patients are to be included in each arm.
* Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab.

  29 patients are to be included in this cohort.